SCNX — Scienture Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1382574 ·
Last close
$0.27
Market Cap
$11.07M
52W High
$2.60
52W Low
$0.24
ADV30
1,179,044
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 343,639 | 335,779 | -2,699,733 | -2,822,371 | 87,734,007 | 8,188,140 | 23,632,481 |
| Mar 2026 | 56,325 | 53,850 | -3,509,499 | -3,402,264 | 80,661,705 | 3,542,754 | 13,841,265 |
| Dec 2025 | -168,699 | -243,812 | -3,154,363 | -28,120,333 | 84,178,330 | 6,662,008 | 14,057,946 |
| Sep 2025 | 590,050 | 574,621 | -4,361,206 | -3,607,361 | 104,830,290 | 355,692 | 22,160,659 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,345,280
Investing CF
$0
Financing CF
$14,835,596
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-83,953,501
Inventory
$210,934
Receivables
$722,545
ST Investments
—
EBIT TTM
$-40,395,968
Pretax Income TTM
$-43,845,409
Interest Exp TTM
$3,449,441
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$821,315
EBITDA
$-12,361,262
Free Cash Flow
$-7,611,433
Enterprise Value
$16,787,558
Total Cash
$8,188,140
Total Debt
$10,689,481
Shares Out
41,064,146
Trailing EPS
$-2.03
Book Value
$1.56
ROE
-53.5%
ROA
-8.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 431,609 | -16,244,792 | -41,512,264 | 84,178,330 | 14,057,946 | 70,120,384 | -13,379,683 |
| Dec 2024 | 136,643 | -14,701,015 | 9,065,798 | 104,853,805 | 25,781,684 | 79,072,121 | -14,265,238 |
| Dec 2023 | 1,363,830 | -4,396,451 | -17,843,574 | 12,532,913 | 11,990,560 | 542,353 | -2,225,192 |
| Dec 2022 | 10,250,168 | -2,040,719 | -3,472,099 | 3,710,026 | 3,367,159 | 763,136 | -1,564,668 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBRX | Moleculin Biotech, Inc. | $11.08M | $0.57 | — |
| OTLC | Oncotelic Therapeutics, Inc. | $11.03M | $0.02 | — |
| MTVA | MetaVia Inc. | $11.00M | $1.67 | — |
| GDTC | CytoMed Therapeutics Ltd | $10.95M | $0.93 | — |
| CALC | CalciMedica, Inc. | $11.47M | $1.68 | — |
News headlines (Yahoo Finance, 1h cache)
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
2026-09-22 12:15 · Yahoo
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
2026-06-18 12:05 · Yahoo
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
2026-06-09 11:46 · Yahoo
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
2026-06-02 12:05 · Yahoo
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
2026-05-18 12:38 · Yahoo
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
2026-05-06 12:05 · Yahoo
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
2026-04-06 12:05 · Yahoo
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
2026-03-30 12:07 · Yahoo
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
2026-08-12 12:05 · Yahoo
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
2026-07-09 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.